BR112023021107A2 - Compostos de tienopirrol - Google Patents

Compostos de tienopirrol

Info

Publication number
BR112023021107A2
BR112023021107A2 BR112023021107A BR112023021107A BR112023021107A2 BR 112023021107 A2 BR112023021107 A2 BR 112023021107A2 BR 112023021107 A BR112023021107 A BR 112023021107A BR 112023021107 A BR112023021107 A BR 112023021107A BR 112023021107 A2 BR112023021107 A2 BR 112023021107A2
Authority
BR
Brazil
Prior art keywords
compounds
thienopirrol
lupus erythematosus
pharmaceutical compositions
treating
Prior art date
Application number
BR112023021107A
Other languages
English (en)
Inventor
J Swank Christopher
G Shore Daniel
Y Canales Eda
H Kinfe Henok
L Mitchell Michael
D Schroeder Scott
E Lazerwith Scott
E Ammann Stephen
K Chang Weng
Yasamin Moazami
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BR112023021107A2 publication Critical patent/BR112023021107A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

compostos de tienopirrol. a presente invenção refere-se, de modo geral, a certos compostos, composições farmacêuticas compreendendo os ditos compostos e métodos de preparo e uso dos ditos compostos e composições farmacêuticas. os compostos e as composições aqui fornecidos podem ser utilizados para tratamento ou prevenção de uma doença autoimune e/ou condição inflamatória, incluindo lúpus eritematoso sistêmico e lúpus eritematoso cutâneo.
BR112023021107A 2021-04-16 2022-04-15 Compostos de tienopirrol BR112023021107A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163176109P 2021-04-16 2021-04-16
US202163216418P 2021-06-29 2021-06-29
US202263305610P 2022-02-01 2022-02-01
PCT/US2022/024984 WO2022221642A1 (en) 2021-04-16 2022-04-15 Thienopyrrole compounds

Publications (1)

Publication Number Publication Date
BR112023021107A2 true BR112023021107A2 (pt) 2023-12-12

Family

ID=81580723

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021107A BR112023021107A2 (pt) 2021-04-16 2022-04-15 Compostos de tienopirrol

Country Status (13)

Country Link
US (2) US11661431B2 (pt)
EP (1) EP4323369A1 (pt)
JP (1) JP2024513945A (pt)
KR (1) KR20230171469A (pt)
AU (1) AU2022257039A1 (pt)
BR (1) BR112023021107A2 (pt)
CA (1) CA3214808A1 (pt)
CO (1) CO2023013397A2 (pt)
CR (1) CR20230478A (pt)
DO (1) DOP2023000219A (pt)
IL (1) IL307203A (pt)
TW (1) TW202302598A (pt)
WO (1) WO2022221642A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230270734A1 (en) * 2021-09-10 2023-08-31 Gilead Sciences, Inc. Thienopyrrole compounds
WO2023247670A1 (en) * 2022-06-24 2023-12-28 F. Hoffmann-La Roche Ag New heterocyclic-carbonyl-cyclic compounds as magl inhibitors

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
GB9718833D0 (en) 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
US6329412B1 (en) 1997-11-04 2001-12-11 Pfizer Inc Bisamidine compounds as antiproliferative agents
AU2006345003A1 (en) 2005-08-12 2008-04-10 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
AU2006279537A1 (en) 2005-08-15 2007-02-22 Irm Llc Compounds and compositions as TPO mimetics
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
JP2009543807A (ja) 2006-07-14 2009-12-10 スミスクライン・ビーチャム・コーポレーション 抗ウイルス剤
RU2470918C2 (ru) 2007-01-15 2012-12-27 Сантен Фармасьютикал Ко., Лтд. НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ IκB КИНАЗЫ β
PT2152701E (pt) 2007-03-12 2016-01-27 Ym Biosciences Australia Pty Compostos de fenil amino pirimidina e suas utilizações
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
JP5486602B2 (ja) 2008-09-26 2014-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾオキサゾール化合物および使用方法
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
ES2583877T3 (es) 2011-06-01 2016-09-22 Janus Biotherapeutics, Inc. Moduladores novedosos del sistema inmunitario
CA2837227C (en) 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2013052263A2 (en) 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
US9873694B2 (en) 2011-10-04 2018-01-23 Janus Biotherapeutics, Inc. Imidazole quinoline-based immune system modulators
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
KR101452579B1 (ko) 2012-08-17 2014-10-21 주식회사 두산 신규 화합물 및 이를 포함하는 유기 전계 발광 소자
AU2014334554B2 (en) 2013-10-14 2018-12-06 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
MX363708B (es) 2013-10-14 2019-03-29 Eisai R&D Man Co Ltd Compuestos de quinolina selectivamente sustituidos.
US20170275287A1 (en) 2014-08-22 2017-09-28 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
MD3277677T2 (ro) 2015-03-30 2021-07-31 Mission Therapeutics Ltd Compuși de 1-ciano-pirolidină utilizați ca inhibitori de USP30
US20180312493A1 (en) 2015-11-04 2018-11-01 Simon Fraser University Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor
AU2016371014B2 (en) 2015-12-17 2021-07-01 Merck Patent Gmbh Polycyclic TLR7/8 antagonists and use thereof in the treatment of immune disorders
CN115650985A (zh) 2016-04-15 2023-01-31 癌症研究科技有限公司 作为ret激酶抑制剂的杂环化合物
TWI746545B (zh) 2016-04-26 2021-11-21 日商大日本住友製藥股份有限公司 經取代嘌呤衍生物
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CA3031675A1 (en) 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
EP4198031A1 (en) 2016-08-08 2023-06-21 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
PT3510033T (pt) 2016-09-09 2022-02-18 Novartis Ag Compostos e composições como inibidores de recetores endossomais do tipo toll
KR102519535B1 (ko) 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 피리딜 치환된 인돌 화합물
CA3070171A1 (en) 2017-07-18 2019-01-24 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2019028301A1 (en) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
JP2021035910A (ja) 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
AU2018364807B2 (en) 2017-11-08 2022-05-19 Council Of Scientific & Industrial Research Purine based compounds as toll-like receptor 9 antagonist
KR20200086709A (ko) 2017-11-14 2020-07-17 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 화합물
CA3085333A1 (en) 2017-12-15 2019-06-20 Bristol-Myers Squibb Company Substituted indole ether compounds
SI3728252T1 (sl) 2017-12-18 2023-11-30 Bristol-Myers Squibb Company 4-azaindolne spojine
JP2021506862A (ja) 2017-12-19 2021-02-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｔｌｒ７／８アンタゴニストおよびそれらの使用
KR20200101402A (ko) 2017-12-19 2020-08-27 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 치환된 인돌 화합물
CN111511730B (zh) 2017-12-19 2023-07-25 百时美施贵宝公司 可用作tlr抑制剂的被酰胺取代的吲哚化合物
AU2018390543A1 (en) 2017-12-19 2020-08-06 Bristol-Myers Squibb Company 6-azaindole compounds
SG11202005695PA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Aryl and heteroaryl substituted indole compounds
WO2019126083A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
KR20200101399A (ko) 2017-12-20 2020-08-27 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 아미노 인돌 화합물
CN111432818A (zh) 2017-12-22 2020-07-17 诺华股份有限公司 用于治疗神经精神性系统性红斑狼疮的吡唑并哌啶衍生物和吡唑并嘧啶衍生物
WO2019220390A1 (en) 2018-05-18 2019-11-21 Novartis Ag Crystalline forms of a tlr7/tlr8 inhibitor
KR20210040085A (ko) 2018-07-31 2021-04-12 메르크 파텐트 게엠베하 Tlr7/8 안타고니스트 및 이의 용도
EP3870589B1 (en) 2018-10-24 2023-09-06 Bristol-Myers Squibb Company Substituted indole dimer compounds
EP3870583A1 (en) 2018-10-24 2021-09-01 Bristol-Myers Squibb Company Substituted indole and indazole compounds
US20220213099A1 (en) 2019-05-07 2022-07-07 Bristol-Myers Squibb Company Prodrug compounds
CN114126713B (zh) 2019-05-09 2023-12-08 百时美施贵宝公司 经取代的苯并咪唑酮化合物
CA3138461A1 (en) 2019-05-23 2020-11-26 Helene Bazin-Lee Vaccine adjuvants based on tlr receptor ligands
KR20220075381A (ko) 2019-10-01 2022-06-08 브리스톨-마이어스 스큅 컴퍼니 치환된 비시클릭 헤테로아릴 화합물
CN114829350A (zh) 2019-10-04 2022-07-29 百时美施贵宝公司 经取代的咔唑化合物
WO2021087181A1 (en) 2019-11-01 2021-05-06 Bristol-Myers Squibb Company Substituted pyrazole compounds as toll receptor inhibitors
EP4149463A1 (en) 2020-05-14 2023-03-22 Merck Healthcare KGaA Tlr7/8 antagonists for the treatment of coronavirus infections
CA3181964A1 (en) 2020-06-11 2021-12-16 Gary L. Schieven Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus
IL299147A (en) 2020-06-22 2023-02-01 Bristol Myers Squibb Co Treatment of rheumatoid arthritis
WO2022022489A1 (zh) 2020-07-27 2022-02-03 江苏恒瑞医药股份有限公司 吲哚稠环类衍生物、其制备方法及其在医药上的应用
CN114075219B (zh) 2020-08-14 2023-11-14 江苏恒瑞医药股份有限公司 喹啉稠环类衍生物、其制备方法及其在医药上的应用
CN114075212B (zh) 2020-08-14 2023-05-12 江苏恒瑞医药股份有限公司 稠合三环类衍生物、其制备方法及其在医药上的应用
JP2023539136A (ja) 2020-08-19 2023-09-13 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ９阻害剤として有用な置換ヘテロアリール化合物
MX2023006193A (es) 2020-11-26 2023-06-09 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina.
WO2022140326A1 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Substituted indole compounds
WO2022140325A1 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. 6-substituted indole compounds

Also Published As

Publication number Publication date
EP4323369A1 (en) 2024-02-21
CA3214808A1 (en) 2022-10-20
WO2022221642A1 (en) 2022-10-20
JP2024513945A (ja) 2024-03-27
IL307203A (en) 2023-11-01
TW202302598A (zh) 2023-01-16
US11661431B2 (en) 2023-05-30
US20220389034A1 (en) 2022-12-08
KR20230171469A (ko) 2023-12-20
DOP2023000219A (es) 2023-11-15
US20230365594A1 (en) 2023-11-16
AU2022257039A1 (en) 2023-10-05
CO2023013397A2 (es) 2023-10-30
CR20230478A (es) 2023-11-30

Similar Documents

Publication Publication Date Title
BR112023021107A2 (pt) Compostos de tienopirrol
BR112018008918A8 (pt) compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
BR112019009529A2 (pt) novos derivados de quinolina
BR112017022349A2 (pt) ?composto, composição, método, e, método para inibir uma proteína irak?
BR112015019794A8 (pt) Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
BR112015024073A2 (pt) Derivados de 3-acetilamino-1-(fenil-heteroaril- aminocarbonil ou fenil-heteroarilcarbonilamino) benzeno para tratamento de doenças hiperproliferativas
BR112017008040A2 (pt) dispositivo de exercício de remo e método de uso do mesmo
BR112018068261A2 (pt) microorganismo comensal transitório para melhorar a saúde do intestino
BR112019001528A8 (pt) novas formulações de comprimidos de cannabus e composições e métodos de produção do mesmo
BR112015010703A8 (pt) Uso de uma composição farmacêutica e composição farmacêutica
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
UY38226A (es) Nuevos derivados de quinolina
BR112018008085A2 (pt) formulação sólida
BR112012025066A2 (pt) mistura fluidificante para composição hidráulica
CY1123554T1 (el) Μικροσφαιριδια που περιεχουν αντιελμινθικες μακροκυκλικες λακτονες
BR112018073862A2 (pt) composição para cuidado dos cabelos
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
BR112021014406A2 (pt) Derivados de tiazolopiridina como antagonistas de receptor de adenosina
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
BR112018074902A2 (pt) composição lubrificante
BR112021019055A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112022010976A2 (pt) Produtos oral com liberação controlada
BR112018011488A2 (pt) banda de rodagem de pneumático para veículo pesado de tipo de engenharia civil